At BIO 2025’s PACE patient advocacy event, industry and patient voices urged stronger incentives and policy protections for Genetically Targeted Technologies (GTTs), citing real‑world benefits observed with antisense oligonucleotides and other precision modalities. Panelists highlighted the MINI Act and other measures to maintain R&D incentives while expanding patient access. Separately at AHA sessions, Ionis Pharmaceuticals’ CEO Brett Monia described the company’s antisense drug Tryngolza as having near‑curative potential for severe hypertriglyceridemia, based on clinical responses reported in twin trials. Patient advocates and industry leaders alike framed the discussion around balancing regulatory incentives, reimbursement policy, and accelerated development for transformative genetic therapies.